Annual Report 2025

NOTESTOTHE CONSOLIDATED FINANCIAL STATEMENTS For the year ended 31 December 2025 87 The United Laboratories International Holdings Limited Annual Report 2025 5. REVENUE AND SEGMENT INFORMATION (Continued) Segment information (Continued) (a) Segment revenue and results (Continued) Year ended 31 December 2024 Intermediate Bulk Finished Segments products medicine products total Elimination Consolidated RMB’000 RMB’000 RMB’000 RMB’000 RMB’000 RMB’000 REVENUE External sales 2,658,691 6,372,683 4,727,563 13,758,937 – 13,758,937 Inter-segment sales 3,198,429 979,071 – 4,177,500 (4,177,500) – Segment revenue 5,857,120 7,351,754 4,727,563 17,936,437 (4,177,500) 13,758,937 Segment profit before research and development expenses 2,215,316 904,596 889,307 4,009,219 Research and development expenses (included in the measurement of segment profit) (113,881) (199,648) (577,228) (890,757) RESULT Segment profit 2,101,435 704,948 312,079 3,118,462 Share of results of an associate (192) Unallocated other income 136,300 Unallocated corporate expenses (114,871) Unallocated other gains and losses, net 184,325 Impairment losses under expected credit loss model, net (168) Finance costs (34,958) Profit before taxation 3,288,898